UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001300
Receipt number R000001580
Scientific Title The effects of angiotensin II receptor blockers (ARBs) on oxidative stress and atherosclerosis in patients with hypertension.
Date of disclosure of the study information 2008/08/11
Last modified on 2008/08/06 15:30:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effects of angiotensin II receptor blockers (ARBs) on oxidative stress and atherosclerosis in patients with hypertension.

Acronym

Anti-oxidant and anti-atherosclerosis effects of ARBs

Scientific Title

The effects of angiotensin II receptor blockers (ARBs) on oxidative stress and atherosclerosis in patients with hypertension.

Scientific Title:Acronym

Anti-oxidant and anti-atherosclerosis effects of ARBs

Region

Japan


Condition

Condition

Patients with hypertension

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The renin-angiotensin system has been clarified to be involved in the process of development and progression of hypertension and atherosclerosis via the production of reactive oxygen species. The aim of this study is to evaluate the effects of angiotensin II receptor blockers (ARBs) on oxidative stress and atherosclerosis in patients with hypertension.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The effects of ARBs on the parameters listed below at baseline, 3, 6, and 12 months after the administrations.
(1) Blood samples (lipid profiles, glucose tolerance, high-sensitive CRP, BNP, etc.)
(2) Oxidative stress marker (8-OHdG, 8-isoprostane, etc.)
(3) Electrocardiography
(4) Echocardiography
(5) Carotid ultrasonography
(6) Pulse wave velocity

Key secondary outcomes

Evaluation of newly developed oxidative stress marker, such as oxidative LDL (negatively charged LDL) and glutathionylated protein


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

ARBs (select one from the following agents)
Olemesartan 10-40mg/day
Losaratan 25-100mg/day
Telmisaratn 20-80mg/day

The assessement will be done at baseline, 3, 6 and 12 months after the treatment.

Interventions/Control_2

Calcium channel antagonist
Nefidipine (Adalat-CR) 20-40mg/day

The assessement will be done at baseline, 3, 6 and 12 months after the treatment.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

85 years-old >

Gender

Male and Female

Key inclusion criteria

The patients with hypertension who was diagnosed as active treatment with antihypertensive agents or as systolic blood pressure of >= 140 mmHg and/or diastolic blood pressure of >= 90 mmHg on at least 2 occasions.

Key exclusion criteria

Severe liver, renal or respiratory diseases
Active infectious and inflammatory diseases
Acute phase of heart failure
Unstable angina
Secondary hypertension

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Satoshi Ikeda

Organization

Nagasaki University School of Medicine

Division name

Second Department of Internal Medicine

Zip code


Address

1-7-1 Sakamoto, Nagasaki

TEL

095-819-7273

Email



Public contact

Name of contact person

1st name
Middle name
Last name Satoshi Ikeda

Organization

Nagasaki University School of Medicine

Division name

Second Department of Internal Medicine

Zip code


Address

1-7-1 Sakamoto, Nagasaki

TEL

095-819-7273

Homepage URL


Email

sikeda@nagasaki-u.ac.jp


Sponsor or person

Institute

Second Department of Internal Medicine, Nagasaki University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 08 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2005 Year 11 Month 03 Day

Date of IRB


Anticipated trial start date

2005 Year 11 Month 01 Day

Last follow-up date

2007 Year 10 Month 01 Day

Date of closure to data entry

2008 Year 10 Month 01 Day

Date trial data considered complete

2008 Year 10 Month 01 Day

Date analysis concluded

2008 Year 10 Month 01 Day


Other

Other related information



Management information

Registered date

2008 Year 08 Month 06 Day

Last modified on

2008 Year 08 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001580


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name